

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 12 of 12 returned.

- 
- ☐ 1. [WO2007091253A2](#). 06 Feb 07. 16 Aug 07. PHARMACEUTICAL COMPOSITIONS COMPRISING CLOPIDOGREL AND VITAMINS WHICH REDUCE HOMOCYSTEINE LEVELS. HALFON, SHLOMO, et al.
- 
- ☐ 2. [WO2007089454A2](#). 18 Jan 07. 09 Aug 07. METHODS FOR ENHANCING SKIN TREATMENTS. FIRST, ERIC R, et al.
- 
- ☐ 3. [US 20070178121 A1](#). Enhancing skin treatment for human patient in their need, involves administering neurotoxin or botulinum toxin to skin area, and calculating dosage of neurotoxin by multiplying surface area of skin by unit of neurotoxin. FIRST E R, et al.
- 
- ☐ 4. [US 20070128228 A1](#). Treating buttock deformity comprises administering botulinum toxin to a buttock of a patient. FIRST E R.
- 
- ☐ 5. [US 20060073208 A1](#). Composition, useful for treating a cosmetic defect (e.g. wrinkles), comprises a botulinum toxin component; and a microsphere component comprising a plurality of swellable microspheres. FIRST E, et al.
- 
- ☐ 6. [US 20060051377 A1](#). Treatment of stretch mark involves administering botulinum toxin to non-surgically formed stretch mark or to the vicinity of the non-surgically formed stretch mark of patient seeking treatment of the stretch mark. FIRST E, et al.
- 
- ☐ 7. [US 20050147625 A1](#). Use of a botulinum toxin to treat motion sickness (pallor, nausea, weakness, malaise, vomiting, vertigo and dizziness). FIRST E R.
- 
- ☐ 8. [US 20050123567 A1](#). Treatment of skin disorder, e.g. warts, corns, calluses, ulcers, neuromas, hammertoes and bunions comprises administering botulinum toxin to location of skin disorder. FIRST E, et al.
- 
- ☐ 9. [US 20040234532 A1](#). Treating an eye disorder, e.g. eye disorder associated with inflammation such as bacterial, fungal, or viral conjunctivitis, uveitis, or keratic precipitates, by administration of Clostridial toxin. FIRST E, et al.
- 
- ☐ 10. [US 6063768 A](#). Treating neurogenic inflammation e.g. rheumatoid arthritis and systemic lupus erythematosus comprising administering a Clostridium botulinum toxin antagonizing neurogenic inflammatory mediator action. FIRST E R.
- 
- ☐ 11. [WO 9639167 A1](#). Compsn. for localised chemical denervation of muscle contains at least 2 neuro-toxins, esp. from Clostridium botulinum, for reducing e.g. spasm, involuntary contractions or tremor. FIRST E R, et al.
- 
- ☐ 12. [GB 2213831 A](#). In vitro culture of bovine embryos using culture medium contg. or conditioned by epithelial cells from oviduct of donor animal. EYESTONE W, et al.
- 

[Generate Collection](#)[Print](#)

Term	Documents
FIRST	2453481
FIRSTS	124
TREATMENT	1013374
TREATMENTS	27828
(TREATMENT AND (FIRST.IN.)).EPAB,JPAB,DWPI.	12
(FIRST.IN. AND TREATMENT).EPAB,JPAB,DWPI.	12

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)